EIC Backs Pregnolia's Groundbreaking Preterm Birth Prediction System
March 12, 2026, 9:34 am
Pregnolia secured significant EIC Accelerator funding, propelling its advanced diagnostic system for preterm birth prediction. The Swiss medtech measures cervical stiffness, a crucial biomarker, aiming to reduce premature deliveries. This innovation promises improved maternal and neonatal outcomes while cutting healthcare costs. The substantial funding accelerates clinical validation and European market launch, marking a pivotal moment for women's health technology.
Preterm birth presents a critical global health challenge. Each year, thousands of babies arrive too soon. In Europe alone, 60,000 to 65,000 women experience premature delivery. Switzerland sees six to seven percent of its births occur before term. This trend strains families emotionally. It burdens healthcare systems financially. The need for effective prediction and prevention is clear.
Swiss startup Pregnolia addresses this urgent need. The company developed an innovative diagnostic system. This technology predicts the risk of premature delivery. It offers a new tool for physicians. It promises to transform prenatal care.
Pregnolia’s core innovation lies in measuring cervical stiffness. Research identified this as a reliable indicator of preterm birth risk. The company’s system quantifies this stiffness. It provides an objective assessment. This moves beyond traditional, subjective evaluations. It equips healthcare providers with vital data.
The technology is already making strides. It established cervical stiffness as a validated biomechanical marker. International clinical studies confirmed its efficacy. Leading maternity clinics use the system. It aids pregnancy diagnostics. It supports data-driven birth management. The device holds CE certification. This marks a significant regulatory achievement.
Recently, Pregnolia secured substantial funding. The European Innovation Council (EIC) Accelerator program provided this support. This grant underscores the EU's commitment. It recognizes the importance of women's health technologies. Especially during pregnancy.
The EIC Accelerator offers comprehensive backing. It provides grant funding up to €2.5 million. It adds equity investments ranging from €0.5 million to €10 million. This blended finance model is powerful. It fuels deep-tech innovation. Beyond financial aid, companies gain access to business acceleration services. They connect with experts, investors, and corporates. This ecosystem support is invaluable.
Pregnolia's EIC funding milestone coincided with its third financing round. This round successfully closed. It brought total funds raised to €3.4 million. This combined investment accelerates the company's mission. It drives the transition from research to clinical application. It prepares the diagnostic tool for wider market release.
The immediate focus remains clear. Pregnolia is advancing clinical validation. It seeks full regulatory approval for its diagnostic test. This test will translate cervical stiffness measurements. It will provide a precise percentage risk of premature birth. Several promising results have already appeared in peer-reviewed journals. These publications reinforce cervical stiffness as a crucial preterm birth biomarker.
The impact of Pregnolia’s system is profound. Earlier, more informed clinical decisions become possible. This improves outcomes for both mothers and newborns. It can reduce avoidable medical interventions. It lowers associated healthcare costs. The emotional toll on families also diminishes. The technology offers hope.
Pregnolia's journey reflects sustained innovation. Sabrina Badir founded the company in 2016. Her work at ETH Zurich and University Hospital Zurich laid the foundation. The company quickly gained recognition. It became a Venture Kick winner. It participated in Venture Leaders Life Science. It consistently ranked among the Top100 Swiss Startups. This progression highlights its potential.
The EIC Accelerator selects companies with transformative technologies. It emphasizes strong commercial promise. In its latest evaluation round, 61 companies received funding. They emerged from 121 interview-stage proposals. Swiss innovation stood out within this competitive landscape. Four Swiss startups secured EIC backing.
Beyond Pregnolia, other Swiss innovators received EIC support. Neutrality, founded in 2019, deploys advanced cybersecurity. It safeguards critical networks for organizations like humanitarian groups. It received blended finance. Verity, established in 2014, secured grant-only funding. It develops AI-powered inventory drones. Its solution already operates in thousands of locations. DePoly, a 2020 startup, also received blended finance. Its technology breaks down PET and Polyester into virgin-grade monomers. This offsets the need for new oil extraction. These companies represent diverse sectors. They demonstrate Switzerland's robust innovation ecosystem.
Pregnolia's next steps involve completing clinical validation. Launching the diagnostic test in Europe is a priority. Simultaneously, the company establishes its regulatory and clinical pathway for future international markets. This expansion strategy aims to make the technology globally accessible.
The widespread adoption of this system could reshape prenatal care. It promises a proactive approach to preterm birth. Lives will improve. Costs will decrease. Pregnolia is at the forefront of this medical revolution. Its EIC funding marks a pivotal moment. The future of preterm birth prediction looks brighter.
Preterm birth presents a critical global health challenge. Each year, thousands of babies arrive too soon. In Europe alone, 60,000 to 65,000 women experience premature delivery. Switzerland sees six to seven percent of its births occur before term. This trend strains families emotionally. It burdens healthcare systems financially. The need for effective prediction and prevention is clear.
Swiss startup Pregnolia addresses this urgent need. The company developed an innovative diagnostic system. This technology predicts the risk of premature delivery. It offers a new tool for physicians. It promises to transform prenatal care.
Pregnolia’s core innovation lies in measuring cervical stiffness. Research identified this as a reliable indicator of preterm birth risk. The company’s system quantifies this stiffness. It provides an objective assessment. This moves beyond traditional, subjective evaluations. It equips healthcare providers with vital data.
The technology is already making strides. It established cervical stiffness as a validated biomechanical marker. International clinical studies confirmed its efficacy. Leading maternity clinics use the system. It aids pregnancy diagnostics. It supports data-driven birth management. The device holds CE certification. This marks a significant regulatory achievement.
Recently, Pregnolia secured substantial funding. The European Innovation Council (EIC) Accelerator program provided this support. This grant underscores the EU's commitment. It recognizes the importance of women's health technologies. Especially during pregnancy.
The EIC Accelerator offers comprehensive backing. It provides grant funding up to €2.5 million. It adds equity investments ranging from €0.5 million to €10 million. This blended finance model is powerful. It fuels deep-tech innovation. Beyond financial aid, companies gain access to business acceleration services. They connect with experts, investors, and corporates. This ecosystem support is invaluable.
Pregnolia's EIC funding milestone coincided with its third financing round. This round successfully closed. It brought total funds raised to €3.4 million. This combined investment accelerates the company's mission. It drives the transition from research to clinical application. It prepares the diagnostic tool for wider market release.
The immediate focus remains clear. Pregnolia is advancing clinical validation. It seeks full regulatory approval for its diagnostic test. This test will translate cervical stiffness measurements. It will provide a precise percentage risk of premature birth. Several promising results have already appeared in peer-reviewed journals. These publications reinforce cervical stiffness as a crucial preterm birth biomarker.
The impact of Pregnolia’s system is profound. Earlier, more informed clinical decisions become possible. This improves outcomes for both mothers and newborns. It can reduce avoidable medical interventions. It lowers associated healthcare costs. The emotional toll on families also diminishes. The technology offers hope.
Pregnolia's journey reflects sustained innovation. Sabrina Badir founded the company in 2016. Her work at ETH Zurich and University Hospital Zurich laid the foundation. The company quickly gained recognition. It became a Venture Kick winner. It participated in Venture Leaders Life Science. It consistently ranked among the Top100 Swiss Startups. This progression highlights its potential.
The EIC Accelerator selects companies with transformative technologies. It emphasizes strong commercial promise. In its latest evaluation round, 61 companies received funding. They emerged from 121 interview-stage proposals. Swiss innovation stood out within this competitive landscape. Four Swiss startups secured EIC backing.
Beyond Pregnolia, other Swiss innovators received EIC support. Neutrality, founded in 2019, deploys advanced cybersecurity. It safeguards critical networks for organizations like humanitarian groups. It received blended finance. Verity, established in 2014, secured grant-only funding. It develops AI-powered inventory drones. Its solution already operates in thousands of locations. DePoly, a 2020 startup, also received blended finance. Its technology breaks down PET and Polyester into virgin-grade monomers. This offsets the need for new oil extraction. These companies represent diverse sectors. They demonstrate Switzerland's robust innovation ecosystem.
Pregnolia's next steps involve completing clinical validation. Launching the diagnostic test in Europe is a priority. Simultaneously, the company establishes its regulatory and clinical pathway for future international markets. This expansion strategy aims to make the technology globally accessible.
The widespread adoption of this system could reshape prenatal care. It promises a proactive approach to preterm birth. Lives will improve. Costs will decrease. Pregnolia is at the forefront of this medical revolution. Its EIC funding marks a pivotal moment. The future of preterm birth prediction looks brighter.